Lexicon Pharmaceuticals, Inc. LXRX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +25.22%
- 1 year
- +4.35%
- Open
- 1.44
- Prev close
- 1.42
- Mkt cap
- 640.74M
- Vol
- 2.02M
- Avg vol
- 2.71M
- EPS
- -0.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.40
- High
- 1.45
- Forward P/E
- -11.86
- Beta
- 1.03
- Short ratio
- 11.53
- Inst. own
- 83.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 2.33
- 200-d avg
- 1.78
- 1y target
- 3.86
5D chart
Signals (52)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 9:35 AM | 20 hours ago |
| RSI: Overbought | Oct 30, 3:50 PM | 3 days ago |
| RSI: Overbought | Oct 30, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 3 days ago |
| RSI: Oversold | Oct 30, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:20 PM | 4 days ago |
Newest 20 of 52.
News
4 days ago globenewswire.com
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its…
-
1 week ago benzinga.com
Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing…
-
1 week ago benzinga.com
Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of…
4 weeks ago benzinga.com
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…